Streamex 将来の成長
Future 基準チェック /56
Streamexは、114.5%と106.4%でそれぞれ年率114.5%で利益と収益が成長すると予測される一方、EPSはgrowで117.5%年率。
主要情報
114.5%
収益成長率
117.50%
EPS成長率
| Medical Equipment 収益成長 | 16.1% |
| 収益成長率 | 106.4% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 21 May 2026 |
今後の成長に関する最新情報
Recent updates
新しいナラティブ • Apr 09
Tokenized Commodity Yield Platform Will Benefit From Growing Real World Asset Adoption
Catalysts About Streamex Streamex operates a capital light platform focused on tokenized commodity assets such as yield bearing gold and planned silver, copper and energy linked products. What are the underlying business or industry changes driving this perspective?分析記事 • Dec 12
Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now
Key Insights BioSig Technologies will host its Annual General Meeting on 18th of December Salary of US$865.7k is part...分析記事 • Dec 14
Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why
Shareholders of BioSig Technologies, Inc. ( NASDAQ:BSGM ) will have been dismayed by the negative share price return...Seeking Alpha • Oct 07
BioSig in acquisition pact with San Antonio Hospital for cardiac signal system
Medical device maker BioSig Technologies, Inc. (NASDAQ:BSGM) announced that the company entered into a purchase agreement with San Antonio Methodist Hospital allowing the latter to acquire its PURE EP System, a cardiac signal processing system. According to a regulatory filing on Thursday, the company executed the deal on Sep. 30 In July, BSGM announced a leasing deal under which the Overland Park Regional Medical Center agreed to acquire the PURE EP System, marking the first transaction since its nationwide launch. "Establishing a contract with a leading national hospital network is a milestone achievement for BioSig Technologies," BSGM Chief Commercial Officer Gray Fleming said at the time. "A leasing option provides a cost-effective and efficient pathway for hospitals to acquire our technology," he added.Seeking Alpha • Sep 08
BioSig: No Changes To Hold Thesis Following Q2 Earnings
Summary BioSig continues to be presented with systematic challenges that place it behind other selective opportunities in med-tech. Cash flows are priced out well into the future and the predictability of these is low in the current landscape. We note updates around PURE EP continue to receive a muted market reaction upon release. Here we reiterate the hold rating on BSGM. From the Portfolio Manager's Desk Unprofitable med-tech continues to face systematic headwinds as the market looks to match mispricings in fundamentals to future expectations. However, risk-assets have caught a bid since June and that's meant high-beta names have clawed back some of the losses incurred in FY22. We've made no changes to our thesis on BioSig Technologies, Inc. (BSGM) from my previous analysis in June. We also covered BioSig in late 2020. We encourage investors to factor a data driven approach in this name until there is some fundamental value to be derived. Investment Summary We reiterate a hold rating on BSGM following Q2 earnings as systematic headwinds remain for this name. We note the stock has caught a bid since the June bounce however we argue this is likely beta related rather than some unidentified or uncorrelated premia BSGM is presenting relative to peers. With cash flows still priced well out into the future, BSGM is one to be watched from the sidelines from now for a defensively positioned equity portfolio. Rate hold on a $1 valuation. Risks to investment thesis Investing in small-cap equities comes with inherent risks that must be factored in before investment decision. Moreover, investing in commercial stage medical device companies carries its own set of downside risks. Being a neutral stance, there is both upside and downside risks to our investment thesis. In addition, small-cap equities can become disconnected from fundamentals upon news releases or wider market actions and display wide volatility in price swings. These risks pose a threat to this investment thesis and must be considered heavily into one's investment reasoning when reading this analysis. Recent upside likely beta related Quantitative analysis of recent stock returns points to the fact the upside is likely due to equity market and sector-beta rather than company-specific risk premia. As seen in Exhibit 1, since the leg upward from the July bounce, BSGM's equity beta to the S&P/500 also shifted well above 1 and has remained buoyant since. This tells us that investors are buyers of BGSM in seeking strategic equity/health care exposure, versus tactical positioning from active managers/investors. Exhibit 1. Up-shift in covariance structure accompanying the latest leg in the BGSM share price suggesting recent upside is likely equity beta versus idiosyncratic risk/return Data: Updata Further evidence of the above is seen in Exhibit 2. As noted, health care as an investment universe has caught a bid since the June bounce along with positioning in risk-assets. However, we note that BSGM's correlation to the medical devices and health care index equipment has also shifted up since May. As a result, we question if the recent upside is a function of certain investors having identified in BGSM that the market consensus has overlooked, or, just a function of sector-beta, as mentioned. We are leaning towards the latter. Exhibit 2. Correlations to med-tech and health care benchmarks also lifting since early May raising questions on where we can attribute the source of recent equity returns from in BGSM Both charts [above and below] demonstrate a tight dispersion between equity market and sector beta and the BGSM share price since it began to tick up in August Data: Updata Pure EP updates still priced in As has been the case with BSGM, the growth engine centres around PURE EP and updates around the same. However, as has also been the case this year, investors have priced in additional updates quickly and with little amplitude. Most recently on 24 August it reported that it had installed a second evaluation system at the Cleveland Clinic, expanding physician access to the company's 'signal' technology. However, the market's reaction was mute, as has been the case previously. In particular, we note the market's muted reaction to the news BSGM will reduce product evaluations down to 60 days from 180-360 days. However, there's still no revenue booked for the segment, in preparation for the commercial rollout. We mentioned in June that, "BSGM likely has revenue tailwinds set to be realised in H2 FY22, with a ramp up in sales predicted into the coming years pending a successful launch." This likely has been overshot and we now look to Q4 to see some form of how the company intends to proceed with its sales strategy looking ahead. The question then turns to what exactly are we paying for today in BSGM. Shares are priced at more than 7.1x book value, on shareholder equity of $6.8mm and book value per share of $0.15. It's also priced at 6.6x enterprise value ("EV") to book value. At this multiple we'd be paying an implied price of $1.00, suggesting the market consensus has the stock fairly discounted at its current market capitalization. Moreover, and looking at the balance sheet, we're buying into a capital structure that is weighted towards equity holders, with $596mm in tangible assets and $317mm in patents that it amortizes on a straight-line basis over 20 years. However, we're not buying into any substantiated return on any of this capital investment, and we are set to pay what looks like fair value for cash flows priced well out into the future. This degree of uncertainty keeps us trigger shy on the name. Technical factors With a lack of fundamental data, we checked the market's psychology around the stock and noted there remains a downside bias in price action. As seen in Exhibit 3, there are downside targets clustered towards the $0.85-$0.92 region. The stock has set a series of lower highs and is again testing the inner resistance line shown below. From this chart, price action appears to be bearish, and unsupportive of near-term upside.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 282 | 195 | N/A | N/A | 1 |
| 12/31/2027 | 97 | 59 | N/A | N/A | 1 |
| 12/31/2026 | 8 | -51 | N/A | N/A | 1 |
| 3/31/2026 | N/A | -507 | -20 | -20 | N/A |
| 12/31/2025 | N/A | -463 | -10 | -10 | N/A |
| 9/30/2025 | 0 | -40 | -8 | -8 | N/A |
| 6/30/2025 | 0 | -26 | -4 | -4 | N/A |
| 3/31/2025 | 0 | -10 | -5 | -5 | N/A |
| 12/31/2024 | 0 | -11 | -5 | -5 | N/A |
| 9/30/2024 | 0 | -15 | -7 | -7 | N/A |
| 6/30/2024 | 0 | -18 | -10 | -10 | N/A |
| 3/31/2024 | 0 | -25 | -13 | -13 | N/A |
| 12/31/2023 | 0 | -29 | -17 | -17 | N/A |
| 9/30/2023 | 0 | -30 | -19 | -18 | N/A |
| 6/30/2023 | 0 | -32 | -20 | -20 | N/A |
| 3/31/2023 | 0 | -27 | -22 | -21 | N/A |
| 12/31/2022 | 0 | -27 | -22 | -22 | N/A |
| 9/30/2022 | 0 | -29 | -24 | -23 | N/A |
| 6/30/2022 | 0 | -30 | -26 | -25 | N/A |
| 3/31/2022 | 0 | -32 | -26 | -25 | N/A |
| 12/31/2021 | 0 | -32 | -27 | -26 | N/A |
| 9/30/2021 | 0 | -34 | -27 | -27 | N/A |
| 6/30/2021 | 0 | -38 | -27 | -26 | N/A |
| 3/31/2021 | 0 | -49 | -28 | -28 | N/A |
| 12/31/2020 | N/A | -52 | -27 | -27 | N/A |
| 9/30/2020 | N/A | -57 | -25 | -24 | N/A |
| 6/30/2020 | N/A | -51 | -22 | -22 | N/A |
| 3/31/2020 | N/A | -40 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -34 | N/A | -15 | N/A |
| 9/30/2019 | N/A | -25 | N/A | -15 | N/A |
| 6/30/2019 | N/A | -23 | N/A | -13 | N/A |
| 3/31/2019 | N/A | -21 | N/A | -11 | N/A |
| 12/31/2018 | N/A | -18 | N/A | -10 | N/A |
| 9/30/2018 | N/A | -17 | N/A | -10 | N/A |
| 6/30/2018 | N/A | -15 | N/A | -9 | N/A |
| 3/31/2018 | N/A | -12 | N/A | -8 | N/A |
| 12/31/2017 | N/A | -13 | N/A | -7 | N/A |
| 9/30/2017 | N/A | -10 | N/A | -6 | N/A |
| 6/30/2017 | N/A | -9 | N/A | -6 | N/A |
| 3/31/2017 | N/A | -12 | N/A | -6 | N/A |
| 12/31/2016 | N/A | -12 | N/A | -5 | N/A |
| 9/30/2016 | N/A | -12 | N/A | -5 | N/A |
| 6/30/2016 | N/A | -11 | N/A | -5 | N/A |
| 3/31/2016 | N/A | -9 | N/A | -4 | N/A |
| 12/31/2015 | N/A | -10 | N/A | -5 | N/A |
| 9/30/2015 | N/A | -10 | N/A | -4 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: STEXは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。
収益対市場: STEX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: STEX今後 3 年以内に収益を上げることが予想されます。
収益対市場: STEXの収益 ( 106.4% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: STEXの収益 ( 106.4% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: STEXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 09:53 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Streamex Corp. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2
| アナリスト | 機関 |
|---|---|
| John Todaro | Needham & Company |
| Scott Henry | Roth Capital Partners |